Protalix Biotherapeutics Inc Share Price TEL AVIV STOCK EXCHANGE
Equities
US74365A1016
Biotechnology & Medical Research
Sales 2024 * | 7.41Cr 2.74TCr 618.22Cr | Sales 2025 * | 13Cr 4.71TCr 1.06TCr | Capitalization | 8.36Cr 3.09TCr 697.7Cr |
---|---|---|---|---|---|
Net income 2024 * | 1.7Cr 628.2Cr 141.91Cr | Net income 2025 * | 7Cr 2.59TCr 584.33Cr | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.66 x |
P/E ratio 2024 * |
5.43
x | P/E ratio 2025 * |
1.41
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.27% |
Latest transcript on Protalix Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30/19/30 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22/19/22 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05/20/05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01/19/01 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01/19/01 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01/14/01 |
1st Jan change | Capi. | |
---|---|---|
+29.79% | 4.82TCr | |
-1.10% | 4.17TCr | |
+43.45% | 4.1TCr | |
-5.26% | 2.88TCr | |
+10.00% | 2.56TCr | |
-22.91% | 1.9TCr | |
+8.24% | 1.29TCr | |
+28.92% | 1.2TCr | |
-2.08% | 1.18TCr |